Nanopharmaceuticals Market to Grow at 9.74% CAGR through 2029
Rising demand
for targeted medicines and increasing investment in research and development is
expected to drive the Global Nanopharmaceuticals Market growth in the forecast
period, 2025-2029.
According to
TechSci Research report, “Nanopharmaceuticals Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2019-2029F”, the
Global Nanopharmaceuticals Market stood at USD 54.38 Billion in 2023 and is anticipated to
project steady growth in the forecast period with a CAGR of 9.74% through 2029. The
market for nanopharmaceuticals has a promising future due to rising R&D
spending, growing demand for personalized medication, and emerging regions that
offer significant room for expansion.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Nanopharmaceuticals Market”
Nnanopharmaceuticals
hold the potential to revolutionize drug delivery, improve treatment outcomes,
and enable more personalized and effective healthcare approaches.
Nanopharmaceuticals offer improved drug delivery systems as a nanoscale drug
carrier, such as liposomes, nanoparticles, and micelles, can encapsulate drugs,
protecting them from degradation, improving solubility, and enabling targeted
delivery to specific tissues or cells for the treatment. This targeted delivery
can enhance drug efficacy, reduce side effects, and increase patient
compliance. Many drugs have poor bioavailability but nanopharmaceuticals can
enhance the bioavailability of the drugs by improving their solubility,
stability, and permeability which enables better absorption and distribution of
the drug within the body, leading to improved therapeutic outcomes. Nanopharmaceuticals
have the potential to enable personalized medicine approaches. The ability to
precisely engineer nanoparticles and control their properties allows for
tailored drug delivery systems based on individual patient conditions which can
lead to optimized treatment strategies and improved patient outcomes.
Nanopharmaceuticals can facilitate combination therapies, where multiple drugs
or therapeutic agents are incorporated into a single nanoparticle. This
approach can enhance treatment effectiveness by targeting multiple disease
pathways simultaneously, overcoming drug resistance, and reducing the need for
multiple drug administrations. Nanopharmaceuticals can also minimize the side
effects associated with traditional drug formulations. By encapsulating drugs
within nanoparticles, they can be protected from degradation in the body,
reducing toxicity to healthy tissues. Additionally, targeted drug delivery
enables lower drug doses to achieve therapeutic effects, further reducing side
effects.
Many start-up
companies are also emerging globally in developing nanopharmaceuticals for the
treatment of chronic diseases. Collaboration among companies and research
institutes is also focused on the development of nanopharmaceuticals. For
instance, a collaboration agreement between Mikart, LLC, a full-service
contract development and manufacturing company, and Nano PharmaSolutions, Inc.,
a cutting-edge nanotechnology business with a patented NanoTransformerTM that
improves the solubility of pharmaceutical active ingredients (API) was
announced in 2022. Using physical vapor deposition (PVD), a method for coating
nanoparticles without the need of polymers or solvents, Nano PharmaSolutions,
Inc. has created the NanoTransformerTM technology. The bioavailability of poorly
soluble medicines is increased by this powerful and high drug loading method.
By reducing development time and R&D expenses, the NanoTransformerTM
Technology creates patient-centered dosage forms. Collaborative efforts between
pharmaceutical companies and nanotechnology-focused companies are harnessing
the potential of nanopharmaceuticals. Such collaborations allow for the
integration of specialized nanotechnology platforms and drug development
expertise, facilitating the development of innovative and effective
nanopharmaceutical products.
Nanopharmaceuticals
have also shown great promise in the treatment of tumors due to their ability
to specifically target cancer cells, enhance drug delivery, and improve
therapeutic outcomes.
Nanopharmaceuticals can be engineered to specifically target disease
cells or tissues. Functionalizing nanoparticles with targeting ligands,
antibodies, or peptides allows for selective recognition and binding to
receptors or markers overexpressed on diseased cells. This targeted approach
minimizes off-target effects and enhances the accumulation of drugs at the
desired site, increasing treatment efficacy.
Rapid
advancements in nanotechnology have enabled the design and fabrication of
nanoparticles with precise control over their size, shape, and surface
properties. This has opened up opened new possibilities for developing
nanopharmaceuticals with enhanced drug delivery capabilities, improved
stability, and targeted therapies. Novel "multifunctional"
nanopharmaceuticals will be developed in the future and administered to the
human body in a variety of ways. Pharma and biotech are likely to enhance
nanopharmaceuticals, particularly for unmet medical needs and minimal costs and
hazards associated with their development.
The Global Nanopharmaceuticals
Market is segmented into form,
application, regional distribution, and company.
Based on form, liposomes
are expected to dominate the market of global nanopharmaceuticals market in the
forecast years. Liposomes can be engineered to have controlled release
properties, allowing for sustained and prolonged drug release over time. This
controlled release profile can enhance therapeutic effectiveness, reduce dosing
frequency, and improve patient compliance. The versatility of liposomes, their ability
to encapsulate various drugs, and their biocompatibility make them attractive
for drug delivery and diagnostic applications in nanopharmaceuticals. Ongoing
research and advancements in liposome-based formulations continue to expand
their potential in improving therapeutic outcomes and addressing healthcare
challenges.
Based on region, North
America is expected to dominate the global nanopharmaceuticals market, as the
region is home to several leading pharmaceutical companies that are actively
involved in the development and commercialization of nanopharmaceuticals.
Companies like Pfizer, Johnson & Johnson, Merck, and Amgen have invested in
nanotechnology research and collaborations to leverage the potential of
nanopharmaceuticals for improved drug delivery and therapeutic outcomes. The
nanopharmaceutical sector in North America continues to thrive with ongoing
research, innovation, and commercialization efforts. It plays a vital role in
advancing drug delivery technologies, personalized medicine, and targeted
therapies, contributing to improved patient care and outcomes.
Major companies
operating in Global Nanopharmaceuticals Market are:
- Merck &
Co., Inc.
- Pfizer Inc.
- Novartis AG
- Abbott
Laboratories Inc.
- GlaxoSmithKline
plc
- Eli Lilly and Company
- Johnson &
Johnson (J&J)
- Gilead
Sciences, Inc.
- AstraZeneca plc
- Celgene
Corporation
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The production
of more effective and focused nanopharmaceutical products with increased
therapeutic efficacy and decreased toxicity is anticipated as a result of the
advancement of superior nanoparticle production processes and the growing
emphasis on targeted drug delivery systems. Though the market is anticipated to
encounter obstacles like high development costs, a lack of standardization, and
security issues with nanopharmaceuticals. Several infectious diseases are being
treated using nanoparticles' physical and chemical properties. The
effectiveness of a therapeutic therapy against infectious diseases has
increased the usage of a nano-vector loaded with the drug. One of the most
recent methods for improving central nervous system (CNS) penetration for the
detection and treatment of neurodegenerative illnesses like Alzheimer's disease
is nanoparticle-mediated drug delivery. More research is still to be done to
enhance the number of FDA-approved nano-drugs, and more research must be
conducted to comprehend how these miraculous particles' special qualities are
developed. Although the area of nanopharmaceuticles has made significant
strides towards getting medications or diagnostics from the lab and into the
clinic, there is still a long way to go. With the increasing investment in
research and development and introduction of novel drug delivery system, the
market is anticipated to experience considerable expansion in the upcoming
years.,” said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“Nanopharmaceuticals Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, Segmented By Form (Liposomes,
Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion,
Nanosuspension, and Others), By Application (Clinical Oncology, Infectious
Diseases, and Cardiovascular Diseases), By Region and Competition, 2019-2029F”,
has evaluated the future growth potential of Global Nanopharmaceuticals Market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Nanopharmaceuticals Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com